1. Home
  2. RTX vs SNY Comparison

RTX vs SNY Comparison

Compare RTX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RTX
  • SNY
  • Stock Information
  • Founded
  • RTX 1934
  • SNY 1994
  • Country
  • RTX United States
  • SNY France
  • Employees
  • RTX N/A
  • SNY N/A
  • Industry
  • RTX Aerospace
  • SNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • RTX Industrials
  • SNY Health Care
  • Exchange
  • RTX Nasdaq
  • SNY Nasdaq
  • Market Cap
  • RTX 194.9B
  • SNY 116.5B
  • IPO Year
  • RTX N/A
  • SNY N/A
  • Fundamental
  • Price
  • RTX $148.67
  • SNY $48.12
  • Analyst Decision
  • RTX Buy
  • SNY Buy
  • Analyst Count
  • RTX 14
  • SNY 2
  • Target Price
  • RTX $143.64
  • SNY $62.50
  • AVG Volume (30 Days)
  • RTX 5.7M
  • SNY 2.1M
  • Earning Date
  • RTX 07-22-2025
  • SNY 07-31-2025
  • Dividend Yield
  • RTX 1.83%
  • SNY 3.32%
  • EPS Growth
  • RTX 37.34
  • SNY 39.56
  • EPS
  • RTX 3.41
  • SNY 5.45
  • Revenue
  • RTX $81,739,000,000.00
  • SNY $48,817,552,946.00
  • Revenue This Year
  • RTX $5.40
  • SNY $3.39
  • Revenue Next Year
  • RTX $5.89
  • SNY $7.05
  • P/E Ratio
  • RTX $43.57
  • SNY $8.83
  • Revenue Growth
  • RTX 15.11
  • SNY N/A
  • 52 Week Low
  • RTX $101.52
  • SNY $45.80
  • 52 Week High
  • RTX $150.75
  • SNY $60.12
  • Technical
  • Relative Strength Index (RSI)
  • RTX 64.50
  • SNY 43.15
  • Support Level
  • RTX $142.98
  • SNY $48.39
  • Resistance Level
  • RTX $146.78
  • SNY $48.80
  • Average True Range (ATR)
  • RTX 2.11
  • SNY 0.58
  • MACD
  • RTX -0.01
  • SNY 0.11
  • Stochastic Oscillator
  • RTX 79.72
  • SNY 29.95

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace and to the defense market across three segments: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Share on Social Networks: